BAKER BROS. ADVISORS LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001263508

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 88 positions · Total reported value $10.31B · Top-10 concentration 81.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 24.2% · 8 new · 6 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, BAKER BROS. ADVISORS LP disclosed 88 equity positions with a combined reported value of $10.31B. The filing implies a focused portfolio: its ten largest positions account for 81.6% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were ONC ($2.13B), INCY ($2.09B), ACAD ($925.28M). By sector, the heaviest allocations are Health Care 98.5%, Other 1.5%.

Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q2 2025 were VRDN ($24.39M), BPMC ($16.09M), ARWR ($14.84M).

Of the 8 positions fully exited versus the prior quarter, the largest were CRSP ($22.26M), CNTA ($17.65M), TSVT ($12.34M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • VRDN VIRIDIAN THERAPEUTICS INC · $24.39M
  • BPMC BLUEPRINT MEDICINES CORP · $16.09M
  • ARWR ARROWHEAD PHARMACEUTICALS IN · $14.84M
  • DNTH DIANTHUS THERAPEUTICS INC · $14.71M
  • CDTX CIDARA THERAPEUTICS INC · $11.07M
  • ACLX ARCELLX INC · $10.99M
  • NUVL NUVALENT INC · $10.98M
  • SYRE SCRIBE THERAPEUTICS INC · $9.38M

Fully Exited (vs previous quarter)

  • CRSP CRISPR THERAPEUTICS AG NAMEN AKT · prev qtr: $22.26M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $17.65M
  • TSVT 2SEVENTY BIO INC · prev qtr: $12.34M
  • BCAX BICARA THERAPEUTICS INC · prev qtr: $10.86M
  • IONS IONIS PHARMACEUTICALS INC · prev qtr: $10.80M · history
  • DYN DYNE THERAPEUTICS INC · prev qtr: $7.03M
  • RGLS REGULUS THERAPEUTICS INC · prev qtr: $4.71M
  • PRME PRIME MEDICINE INC · prev qtr: $2.05M

Insider Transactions (Form 4)

Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 2,000 $396.61 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 13,740 $388.29 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 60,400 $383.01 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 81,729 $98.51 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 4,703 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 151,916 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 8,742 $98.51 SEC filing
2026-11-04 Buy MADRIGAL PHARMACEUTICALS, INC. 10,080 $368.11 SEC filing

All insider transactions →

Fund Profile

Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73446 (status: Approved), registered 2012-03-05
  • Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 83 positions · $19.13B reported value (Q2 2026)
  • Top 10 holdings = 74.7% of reported value
  • Largest position: INCY (INCYTE CORP) at 18.2%
  • Average position size: $230.45M

Sector Tilt

  • Health Care 99.4%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
  • 59 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The BAKER BROS. ADVISORS LP fund appears to maintain a cautious stance, with a focus on Health Care sector, suggesting a belief in the stability and growth potential of this sector. 2. Key Moves: - Added: Revolution Medicines Inc. (RVMD) and Insmed Inc. (INSM), with significant increases in share count. - Reduced: None explicitly noted, but the slight increase in the share count of Incyte Corp. (INCY) indicates a minor addition. - Hold: The majority of holdings were held steady, with no significant changes in share count or position action. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it added new positions and increased existing ones. - Sector Bias: Strong bias towards the Health Care sector, with 83% of the total value allocated to it. - Risk Appetite: The risk appetite is moderate, with a focus on established companies in the Health Care sector and no significant reduction in positions. 4. Per-Holding One-Liner: - INCY: Biotechnology company focused on developing therapies for immune-mediated diseases. - ONC: Biopharmaceutical company specializing in the development of treatments for various diseases. - RVMD: Biotechnology company focused on developing novel therapies for cancer and other diseases. - MDGL: Biotechnology company focused on the development of therapies for rare genetic diseases. - ACAD: Biotechnology company focused on developing treatments for neurological disorders. - KYMR: Biotechnology company focused on developing treatments for cancer and other diseases. - INSM: Biotechnology company focused on the development of therapies for rare genetic diseases. - KOD: Biotechnology company focused on the development of therapies for rare genetic diseases. - RYTM: Biotechnology company focused on the development of therapies for neurological disorders. - PRAX: Biotechnology company focused on the development of therapies for various diseases. 5. One-Sentence Style Summary: BAKER BROS. ADVISORS LP maintained a conservative approach, focusing on Health Care sector with a few strategic additions, reflecting a belief in the sector's stability and growth prospects.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 98.5%
Other 1.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.80M $2.13B 20.66%
Form 4 · 1 →
20.66%
Hold
2 30.74M $2.09B 20.31%
Form 4 · 1 →
20.31%
Hold
3 42.90M $925.28M 8.98%
8.98%
Hold
4 7.71M $776.23M 7.53%
7.53%
Add
5 33.72M $717.62M 6.96%
6.96%
Add
6 1.98M $598.02M 5.80%
Form 4 · 5 →
5.80%
Hold
7 5.60M $354.15M 3.44%
3.44%
Hold
8 9.36M $344.54M 3.34%
3.34%
Add
9 6.65M $290.27M 2.82%
2.82%
Add
10 6.41M $183.41M 1.78%
1.78%
Add
11 11.05M $102.61M 0.99%
0.99%
Hold
12 2.77M $100.82M 0.98%
0.98%
Add
13 7.31M $95.78M 0.93%
0.93%
Add
14 27.53M $94.41M 0.92%
0.92%
Hold
15 5.46M $87.33M 0.85%
0.85%
Hold
16 1.63M $83.82M 0.81%
0.81%
Hold
17 2.82M $78.16M 0.76%
0.76%
Hold
18 10.89M $75.65M 0.73%
0.73%
Hold
19 2.32M $72.88M 0.71%
0.71%
Hold
20 5.45M $72.76M 0.71%
0.71%
Add
21 17.31M $64.57M 0.63%
Form 4 · 86 →
0.63%
Hold
22 10.17M $54.71M 0.53%
0.53%
Add
23 4.63M $52.59M 0.51%
0.51%
Hold
24 3.73M $52.21M 0.51%
0.51%
Hold
25 2.51M $52.03M 0.51%
0.51%
Add
26 2.12M $44.54M 0.43%
0.43%
Add
27 3.88M $44.22M 0.43%
0.43%
Hold
28 3.77M $42.46M 0.41%
0.41%
Hold
29 368.92K $39.28M 0.38%
0.38%
Add
30 4.87M $32.70M 0.32%
0.32%
Hold
31 574.38K $30.21M 0.29%
0.29%
Add
32 689.49K $28.99M 0.28%
0.28%
Add
33 2.68M $25.10M 0.24%
0.24%
Add
34 1.74M $24.39M 0.24%
0.24%
New
35 4.92M $22.17M 0.21%
0.21%
Hold
36 223.84K $21.17M 0.20%
0.20%
Hold
37 640.88K $20.84M 0.20%
0.20%
Hold
38 37.76K $20.81M 0.20%
0.20%
Reduce
39 1.69M $19.00M 0.18%
0.18%
Hold
40 12.88M $18.17M 0.18%
0.18%
Reduce
41 337.05K $17.85M 0.17%
0.17%
Add
42 324.63K $17.32M 0.17%
0.17%
Reduce
43 125.54K $16.09M 0.16%
0.16%
New
44 5.50M $15.23M 0.15%
0.15%
Hold
45 939.17K $14.84M 0.14%
0.14%
New
46 991.69K $14.83M 0.14%
0.14%
Reduce
47 789.76K $14.71M 0.14%
0.14%
New
48 665.37K $13.54M 0.13%
0.13%
Add
49 1.46M $13.39M 0.13%
0.13%
Hold
50 370.21K $11.59M 0.11%
0.11%
Add

FAQ

What did BAKER BROS. ADVISORS LP buy in 2025-Q2?

In its 2025-Q2 13F filing, BAKER BROS. ADVISORS LP reported 88 equity positions worth $10.31B in aggregate; its largest disclosed positions were ONC ($2.13B), INCY ($2.09B), ACAD ($925.28M).

How large is BAKER BROS. ADVISORS LP's portfolio?

BAKER BROS. ADVISORS LP reported $10.31B of long equity holdings across 88 positions as of 2025-Q2. Top-10 holdings account for 81.6% of reported value.

What is BAKER BROS. ADVISORS LP's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/baker-bros-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →